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Endothelial apoptosis in scleroderma: comment on the
article by Black et al
To the Editor:
Apoptotic endothelial cells have been found in the
early inflammatory stages of systemic sclerosis (SSc) and
localized scleroderma (1), and experimental data on humans
suggest a possible role of anti–endothelial cell antibodies in
this process (1,2). Interferon-a (IFNa) causes apoptosis of
human dermal microvascular endothelial cells in vitro, in a
time- and dose-dependent manner (3). Theoretically, if admin-
istered to patients with SSc, IFNa should cause a worsening of
the disease. This assumption seems to be confirmed by the
results of the recent trial of IFNa in diffuse cutaneous
scleroderma reported by Black et al (4). Endothelial apoptosis
may be of importance in the pathogenesis of SSc and localized
scleroderma.
Tihomir Štefanec, MD
St. Vincent’s Hospital and Medical Center
New York, NY
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Lipoprotein(a) levels and atherosclerosis in
rheumatoid arthritis: comment on the article by
Asanuma et al
To the Editor:
Asanuma et al (1) report an increase in levels of
lipoprotein(a) (Lp[a]) and a higher prevalence of the disad-
vantageous S3 apolipoprotein(a) (Apo[a]) phenotype in pa-
tients with rheumatoid arthritis (RA) compared with appar-
ently healthy controls. They report no difference in Lp(a)
levels between RA patients with atherosclerotic disease and
those without. They hypothesize that high Lp(a) levels may
contribute to the increased incidence of vascular disease in RA.
The association of RA with increased cardiovascular
mortality is well documented (2). There is, however, no direct
evidence that this increased cardiovascular mortality is due to
increased atherosclerotic disease, particularly coronary artery
disease. This can currently only be inferred, since other cardiac
pathology in RA (such as pericarditis) rarely causes significant
hemodynamic compromise (3). The finding of elevated Lp(a)
levels in RA patients compared with controls is important in
this respect, because they may lead to accelerated atheroscle-
rosis and early ischemic heart disease (IHD) in these patients.
The absence of a difference in Lp(a) levels between
RA patients with atherosclerosis and those without in the study
by Asanuma and colleagues is not surprising, since very few
patients had atherosclerotic disease as defined by the authors.
The definition of atherosclerotic disease was based on “blunt”
clinical end points (history of IHD, cerebral infarction, or
transient ischemic attacks). These are highly specific but very
insensitive. Postmortem studies (deaths from all causes) have
shown rates of definite, though nonocclusive, coronary ather-
oma in up to 60% of young adults (4). It is very likely that in
the age groups studied by Asanuma et al, atheroma would be
a virtually ubiquitous finding. In addition, cardiac ischemia
may be clinically silent, particularly in a population of RA
patients who are limited in exertion due to their joint disease.
We have prospectively assessed 50 randomly selected
hospital outpatients with RA, ages 40–70 years. On clinical
grounds alone, using the Rose questionnaire (5), only one-
fourth of them would have been judged to have IHD. How-
ever, the true prevalence of IHD was 50%, as assessed by
combining clinical information with findings on electrocardi-
ography and 201thallium myocardial perfusion imaging with
single-photon–emission computed tomography using pharma-
cologic (adenosine) stress. Half of the patients with clinically
silent IHD were at high risk for a major cardiac event (6). The
crude definition of atherosclerotic vascular disease used in the
study by Asanuma et al may have led to the inclusion in the
nonatherosclerotic group of a substantial number of patients
with significant but silent atherosclerosis. This may have
masked a potential difference in Lp(a) levels between the 2
RA groups.
Although it is well established that cardiovascular
mortality is increased in RA, the cause remains elusive.
Further studies are required to confirm whether atherosclero-
sis is accelerated in RA, to identify the risk factors for this, and
to allow earlier intervention to prevent the complications of
advanced atherosclerotic disease.
M. J. Banks, MB, ChB, MRCP
G. D. Kitas, PhD, MD, MRCP
Dudley Group of Hospitals
NHS Trust
Dudley, UK
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Reply
To the Editor:
We thank Drs. Banks and Kitas for their interest in our
recent study concerning serum Lp(a) and Apo(a) phenotypes
in patients with RA. They have made a detailed clinical
evaluation of IHD in RA patients (Banks MJ, Flint EJ, Bacon
PA, Kitas GD. Expression and prevalence of ischaemic heart
disease in rheumatoid arthritis [abstract]. Arthritis Rheum
1998;41 Suppl 9:S209.). One-fourth of the subjects in their
study were judged to have IHD based on clinical data alone. In
addition, the prevalence of IHD as assessed by electrocardi-
ography and 201thallium myocardial perfusion imaging with
single-photon–emission computed tomography was 50%. Al-
though they mention that there was no difference in Lp(a)
levels between RA patients with and those without atheroscle-
rosis in our study, we did demonstrate that Lp(a) levels tended
to be higher in RA patients with atherosclerotic complications
(mean 6 SD 35.7 6 26.8 mg/dl [n 5 11]) than in those without
(26.8 6 22.2 mg/dl [n 5 120]). The incidence of atherosclerotic
disease was 8.4% (11 of 131) in our RA patients, but these
patients were evaluated based on the clinically obvious out-
come of atherosclerotic changes, as Drs. Banks and Kitas point
out. In this context, we agree that further studies are required
to confirm the relationship between atherosclerosis and Lp(a)
or Apo(a) phenotypes in RA patients. However, our study
showed that an increased Lp(a) level in RA patients was
associated with S3 phenotype predominance, which might be
genetically determined. This finding may help to improve our
understanding of the genetic background of RA patients,
especially those with atherosclerotic diseases.
Yu Asanuma, MD, PhD
Shinichi Kawai, MD, PhD
St. Marianna University School of Medicine
Kawasaki, Japan
Absence of human retrovirus 5 in French patients
with rheumatoid arthritis: comment on the article by
Griffiths et al
To the Editor:
The etiology of rheumatoid arthritis (RA) remains
unknown, although several viral candidates have been pro-
posed over the last few years (1). The recent report by Griffiths
and colleagues (2) describing the possible involvement of
human retrovirus 5 (HRV-5) in rheumatic diseases is of
particular interest in view of increasing evidence that retrovi-
ruses may be implicated in other autoimmune disorders,
including Sjögren’s syndrome, multiple sclerosis, and, contro-
versially, insulin-dependent diabetes (3–6).
Figure 1. Ethidium bromide–stained 3% agarose gels of second-
round nested polymerase chain reaction (PCR) products. The molec-
ular weight markers (M) are Hinf I digests of phage f174 DNA. A,
PCR for detection of human retrovirus 5 (HRV-5). Lanes 1–19,
rheumatoid arthritis DNA samples; lanes 20–30, control DNA sam-
ples; lanes 31 and 37–40, water controls; lanes 32–36, pHRV5.1
plasmid dilution series (;103, 102, 10, 1, and 1021 copies, respectively)
used as a positive control. Arrow indicates the expected 157-bp bands.
B, HRV-5–spiked PCR. Lane contents are the same as in A, but with
100 copies of pHRV5.1 plasmid added to alternate samples. Arrows
indicate the expected 157-bp bands.
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HRV-5 is a novel exogenous retrovirus initially identi-
fied in salivary gland tissue of a patient with Sjögren’s syn-
drome (7). Using a highly sensitive polymerase chain reaction
(PCR) technique, Griffiths et al detected HRV-5 proviral
DNA sequences in 48% of synovial samples (12% of blood
samples) from patients with RA and in 60% of synovial
samples from patients with reactive arthritis or osteoarthritis,
but in none of 13 samples of normal synovium (2). In an
attempt to confirm these important findings, we conducted a
PCR-based study on a cohort of 40 French patients with RA or
carpal tunnel syndrome who were undergoing hand surgery
(joint replacement, synovectomy, arthrodesis, tendon repair,
or neurolysis) at Grenoble Teaching Hospital.
Synovial membrane was obtained from 19 patients with
RA and from 21 non-RA controls during surgery for mechan-
ical carpal tunnel syndrome. Biopsy specimens were stored at
270°C, and DNA was extracted and purified using QIAmp
DNA Minikit reagents according to the instructions of the
manufacturer (Qiagen, Crawley, UK). Extracted DNA was
quantified by Hoechst H33258 dye binding (8), and its suitabil-
ity for PCR analysis confirmed by amplification of the human
single-copy gene, pyruvate dehydrogenase (PDH), as previ-
ously described (9). One microgram of the extracted DNA was
tested by nested PCR for the presence of HRV-5 sequences,
using the pol primer set and thermal cycling conditions de-
scribed by Griffiths et al (2). The HRV-5 pol–containing
plasmid pHRV5.1 (generously donated by Dr. Griffiths) was
used as a positive control in each experiment. Single copies of
the pHRV5.1 plasmid were detectable by this nested PCR.
HRV-5 DNA sequences were not detected in any of
the 40 samples analyzed, despite testing in triplicate (Figure
1A). Reduction of the annealing temperature from 52°C to
45°C also failed to generate PCR products from the test
samples. In order to exclude the possibility that the negative
results might be due to copurified inhibitors of PCR, alternate
DNA samples were spiked with 100 copies of pHRV5.1. No
evidence of PCR inhibition was observed (Figure 1B). The
suitability of the DNA for PCR analysis was confirmed by
amplification of the PDH gene (data not shown).
We have thus been unable to confirm the findings of
Griffiths et al in this group of patients. The reason(s) for this
discrepancy is unclear because the same PCR methodology
was utilized, although we cannot exclude the possibility that
unrecognized technical differences may have accounted for the
disparate results. However, the discrepancy may possibly be
related to the different geographic areas from which the
patients were selected, i.e., southeastern France versus Lon-
don. It is well known that the geographic distribution of other
exogenous retroviruses, such as human T lymphotropic virus
type I, may be very heterogeneous (10). Alternatively, the
populations studied may have differed in the duration and
severity of their disease or in their treatment. The patients in
our study all had had RA for at least 5 years (average 7.5
years), and all were receiving treatment with methotrexate,
steroids, or other second-line drugs. Further work is clearly
required to define more precisely the prevalence of this novel
human retrovirus in various patient populations.
Supported by Wellcome Trust grant 057298/Z/99/Z/SRD.
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Reply
To the Editor:
Gaudin and colleagues report their failure to confirm
our detection of HRV-5 DNA in synovial membranes from
patients with RA. Having reviewed their methods, we can see
no obvious methodologic or technical explanation for this
discrepancy, and therefore it is likely that the difference in
results is due to some difference in the tissue specimens
studied.
The patients in our study were from the UK, whereas
those studied by Gaudin et al were residents of southeastern
France. We do not believe that this geographic difference can
explain the data. In addition to patients from the UK, HRV-5
has been detected in individuals from France, Italy, and the US
(Calvez V, Corbellino M, Patel R: personal communications),
although the presence of HRV-5 in patients with RA was not
studied by all of these groups. In one of these studies (Patel R
et al: manuscript in preparation), HRV-5 proviral DNA was
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detected in a high proportion of synovial membrane samples
from patients undergoing revision arthroplasty. DNA from
some of these samples was sent to us. We were able not only to
confirm these findings, but also to detect sequences in the gag
region of HRV-5, which we have recently cloned (Griffiths DJ
et al: unpublished data). This confirms that the findings could
not have been due to contamination.
It would be of interest to know whether any of the
patients studied by Gaudin and colleagues had detectable
HRV-5 in their peripheral blood, given that we detected the
virus in 12% of RA patients. The suggestion that cortico-
steroids might activate or inhibit HRV-5 expression is worthy
of discussion, especially since one of the closer relatives of
HRV-5, murine mammary tumor virus, is activated by steroid
hormones. Five of the 12 RA patients in our study whose
synovial membranes contained detectable HRV-5 DNA were
receiving steroids, although the numbers are too small to
determine an effect by correlation. We believe that the effect
of steroids on HRV-5 expression would be best studied by
directly examining infected or transfected cell lines.
Apart from technical factors, we suggest that one
explanation for the observed differences between our findings
and those of Gaudin and colleagues might be the source of
tissue and the way it was obtained. Samples from the majority
of the patients in our study were undergoing “medical” arthro-
scopy, which tends to select for patients with active disease. In
this procedure, synovial villae are sampled under direct visu-
alization. Such villae are highly enriched for inflammatory
cells, whereas synovium obtained at surgery from patients with
RA or carpal tunnel syndrome may be more mesenchymal or
fibrofatty in nature. In our study, the number of subjects was
too small to examine a relationship to inflammation by seeking
clinicopathologic correlations. A more direct approach would
be to examine the cellular tropism of HRV-5. This will address
not only the issue of sampling, but also whether the virus is
involved in the pathogenesis of arthritis or, more critically,
whether it is a “passenger” that is tropic to a cell type
concentrated in inflamed synovium. Such studies are currently
in progress.
David J. Griffiths, PhD
University College London
London, UK
Patrick J. W. Venables, MD, FRCP
Kennedy Institute of Rheumatology
London, UK
Specificity of antineutrophil cytoplasmic antibody:
comment on the article by Choi et al
To the Editor:
The case report by Choi et al in the February 1999
issue of Arthritis & Rheumatism (Choi HK, Merkel PA, Cohen
Tervaert JW, Black RM, McCluskey RT, Niles JL. Alternating
antineutrophil cytoplasmic antibody specificity: drug-induced
vasculitis in a patient with Wegener’s granulomatosis. Arthritis
Rheum 1999;42:384–8.) provides further evidence that auto-
immunity can be triggered by many agents, of which drugs are
one. Drugs have been known to induce systemic lupus ery-
thematosus, pemphigus, pemphigoid, and vasculitis character-
ized by the presence of specific autoantibodies.
Approximately 28 cases of drug-induced antineutro-
Table 1. Results of the ANCA Combi test in patients who were positive for cANCA or pANCA by immunofluorescence*
Patient PR3 MPO BPI Elastase Cathepsin G Lysozyme Lactoferrin
ANCA type
(titer)†
1 2 2 2 2 2 2 2 c (1:320)
2 2 2 1 2 1 2 2 c (1:10)
3 1 1 1 1 2 2 2 c (1:280)
4 1 2 2 2 2 2 2 c (1:80)
5 1 2 2 2 2 1 2 c (1:160)
6 2 2 1 2 2 2 2 p (1:80)
7 1 2 1 2 2 1 2 c (1:80)
8 2 2 1 2 1 1 2 p (1:160)
9 1 2 1 2 2 2 2 p (1:40)
10 1 2 2 1 2 2 1 p (1:280)
11 2 1 1 2 2 2 2 p (1:640)
12 1 2 1 2 2 2 2 p (1:20)
13 1 2 1 2 2 2 2 c (1:32)
14 2 2 1 2 2 2 2 c (1:2)
15 2 2 1 1 2 2 2 p (1:40)
16 1 1 1 1 1 1 2 p (1:20)
17 1 2 1 2 2 2 2 c (1:40)
18 1 2 1 2 2 1 2 c (1:160)
19 2 2 1 1 1 2 2 c (1:80)
* ANCA 5 antinuclear cytoplasmic antibody; PR3 5 proteinase 3; MPO 5 myeloperoxidase; BPI 5 bactericidal permeability–increasing protein;
c 5 classic ANCA; p 5 perinuclear ANCA.
† Titers . 1:32 considered positive.
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phil cytoplasmic antibodies (ANCA) have been reported in the
literature. The most common association is with antithyroid
drugs (Gunton JE, Stiel J, Caterson RJ, McElduff A. Anti-
thyroid drugs and antineutrophil cytoplasmic antibody positive
vasculitis: a case report and review of the literature. J Clin
Endocrinol Metab 1999;84:13–6). Propylthiouracil (PTU),
used in the treatment of Graves’ disease, has been implicated
in the development of ANCA in 88% of the reported cases of
drug-induced ANCA in Graves’ disease patients. Drug-
induced ANCA, however, has also been reported in associa-
tion with other drugs, such as hydralazine, sulfasalazine, and
minocycline.
The type of ANCA reaction in .80% cases is of
perinuclear ANCA (pANCA), with undifferentiated ANCA in
;15% of cases and classic ANCA (cANCA) in 10%. Among
cases in which the specificity of the ANCA was determined,
myeloperoxidase (MPO) was found in ;80%. The report by
Choi et al is unusual in that the patient was already diagnosed
as having ANCA-positive Wegener’s granulomatosis and sub-
sequently developed Graves’ disease; in most other cases, the
underlying disease was only Graves’ disease. However, in this
and other cases, the ANCA positivity was triggered ;3 months
after treatment with PTU. The drug has been shown to
accumulate in neutrophils and bind to MPO, changing its
structure. This binding may result in alteration of the structure
and conformation of the antigen, hence allowing initiation of
an autoimmune response in genetically susceptible individuals.
The immune response to drug-induced antigen alteration
subsides when the triggering agent is withdrawn. Thus, it is
believed that when Choi and colleagues’ patient began PTU
treatment after Graves’ disease was diagnosed, he developed
pANCA of MPO specificity. The antibody titers of cANCA in
this case decreased upon immunosuppression, whereas the
pANCA titer continued to increase with PTU therapy, and the
reverse was true when the drug was withdrawn.
Another comment pertinent to the report by Choi et al
is that alternating ANCA specificity can also occur due to the
concomitant presence of several ANCA specificities. Table 1
shows results we obtained in correlating the immunofluores-
cence pattern pANCA with the antigen-specific response in 19
cANCA- or pANCA-positive vasculitis patients. We used the
ANCA Combi test, an enzyme-linked immunosorbent assay
technique developed by Orgentec (Mainz, Germany), in which
a microplate was coated with the antigens proteinase 3 (PR3):
MPO, bactericidal permeability–increasing protein (BPI), elas-
tase, cathepsin G, lysozyme, and lactoferrin, which had been
previously purified by affinity chromatography. The ANCA
Combi test is specific for autoantibodies directed to these
antigens, without cross-reactivity. The results indicated that
slides read as showing cANCA or pANCA by immunofluores-
cence do not always show PR3 or MPO reactivity on the
ANCA Combi, but do show reactivity with other antigens.
ANCA BPI appears to be masked as or associated with
cANCA or pANCA in a high number of cases.
In conclusion, alternating ANCA specificity could be
due to transient superimposed immunoreactivity within the
same disease, as well as to the simultaneous presence of 2
distint vasculitic diseases, 1 of them drug induced, as shown in
the report by Choi et al.
Sueli B. Maciel, BS
Morton A. Scheinberg, MD, PhD






Comparison of Dutch and US patients’ perceptions of
the effects of Wegener’s granulomatosis on health,
function, income, and interpersonal relationships:
comment on the article by Hoffman et al
To the Editor:
We read with great interest the article by Hoffman et
al (1), in which patient-perceived effects of Wegener’s granu-
lomatosis (WG) on health, function, income, and interpersonal
relationships were reported. From this investigation it could be
concluded that WG has a major impact on quality-of-life
issues.
Some limitations of this study, however, were appar-
ent. One of the major limitations was that the investigation was
performed as a single-site study. Whether the results are also
applicable to patients in other parts of the world is still
unknown. We thus studied patient-perceived effects of WG in
our patient population in Groningen and compared our find-
ings with those obtained in the Cleveland study. The question-
naire that was used by Hoffman et al was translated into Dutch
and sent to 91 WG patients who are regularly seen at the
outpatient clinic of University Hospital Groningen. All pa-
tients met the American College of Rheumatology criteria for
WG (2). Our study design was approved by the formal ethics
review committee.
Seventy-nine of the 91 patients (87%) responded
(Cleveland study 60 of 100 patients). Sixty-four of the 79 lived
with a partner, and 59 of these (92%) also responded (Cleve-
land study 43 of 44 partners). Dutch patients were comparable
with the Cleveland patients with respect to sex, age, race,
median duration of disease, distribution of organ involvement,
and patient-reported comorbidity.
The patient-reported delay from onset of symptoms to
diagnosis of WG was, however, much shorter in the Dutch
patients (mean 9.4 months versus 16.8 months in the Cleveland
patients), possibly due to a greater awareness of WG in our
region and hence more widespread use of the antineutrophil
cytoplasmic antibody (ANCA) test. Interestingly, in a study of
35 patients (3) that was performed in 1986, at the time ANCA
testing had only recently been introduced in our laboratory (4),
we also found a longer delay in diagnosis (17.7 months),
comparable with the delay reported by the Cleveland patients.
Another observed difference between our patients and those
reported by Hoffman et al was that the Dutch patients were
less often told that their problems were “psychosomatic” (14%
versus 25% of the Cleveland patients).
Patient happiness was equally effected by WG in The
Netherlands and the US (32% Dutch patients unhappy versus
33% Cleveland patients), although somewhat fewer Dutch
patients reported being depressed because of their disease
LETTERS 2495
(33% versus 43% of the Cleveland patients), and, additionally,
fewer Dutch patients reported suicidal thoughts (7% versus
14% of the Cleveland patients).
Remarkably similar findings were found with respect
to the impact of WG on employment status. Our patients
missed work for long periods somewhat more frequently, and
more patients worked a reduced number of hours. In The
Netherlands, almost all patients changed duties at work (Table
1). Finally, 27% of our patients were disabled and receiving
disability benefits (Cleveland patients 31%).
The most remarkable differences between Dutch and
American patients were found in the answers to questions
pertaining to interpersonal relationships. Whereas 47% of the
Cleveland patients thought that their illness brought their
family closer together, only 16% of our patients thought so.
Not only did fewer Dutch patients believe that their relation-
ship with their partners improved (20% versus 50% of the
Cleveland patients), but fewer Dutch patients also reported a
worsening of their relationship (9% versus 18% of the Cleve-
land patients).
Interestingly, the degree of agreement between pa-
tients and partners about the effect of the illness on their
relationships was higher in our patient group than in the
Cleveland group (observed agreement in The Netherlands
84.4%, chance agreement 53.8% [k 5 0.66]; observed agree-
ment in Cleveland 52.8%, chance agreement 35.5% [k 5
0.27]).
Finally, partners of Dutch patients were less often
concerned about the long-term effects of the disease and
treatment (35% versus 70% of the Cleveland patients) and
about implications of the disease on financial security (5%
versus 28% of the Cleveland patients).
In conclusion, our study findings are consistent with
those of Hoffman et al (1) and demonstrate that WG is
associated with substantial medical morbidity resulting in
physical and occupational disability. Important differences,
however, exist with respect to the influence of WG on inter-
personal relationships. We hypothesize that most of these
latter differences are due to cultural and socioeconomic dif-
ferences between The Netherlands and the US.
M. M. Boomsma, MD
C. A. Stegeman, MD, PhD
J. W. Cohen Tervaert, MD, PhD
University Hospital
Groningen, The Netherlands
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Reply
To the Editor:
We are very pleased that our Dutch colleagues have
found our questionnaire helpful to study patient-reported
effects of WG on health, function, and income. In an effort to
ensure that patient-reported information was similar to that
perceived by the primary physician responsible for the pa-
tients’ care, restricting our cohort to patients who had been
evaluated by the senior author was very useful. In this manner,
we were able to determine that physician-recorded medical
events were in fact similar to those reported by patients. This
observation enhanced the credibility of patient-reported psy-
chosocial and economic information, which was supplemented
by information derived from Internal Revenue Service tax
returns. This degree of rigor would have been difficult to apply
to patients accrued in a multicenter study, for whom multiple
physicians would have been responsible for care and documen-
tation of disease impact.
It is not surprising to learn, from Boomsma and
colleagues, that patients who have the same disease but
different ethnic, socioeconomic, or cultural backgrounds may
differ with regard to the impact of any specific illness. This may
contribute to compliance in responding to health question-
naires, to development of coping strategies for dealing with
pain, to disability, to economic challenges, and to interpersonal
relationships. Despite the fascinating differences that may
distinguish patients surveyed in Cleveland and those in The
Netherlands, it is clear from both studies that WG exacts a
dramatic toll on those who are affected. We look forward to
Table 1. Major differences between the Cleveland Wegener’s granulomatosis (WG) patient population and the Groningen WG patient population
Hoffman et al (1)* Boomsma et al* Difference†
Impact on financial security 28 5 5.6
Bring the family closer together 47 16 2.9
Relationship with partner improved 50 20 2.5
Relationship with partner worsened 18 9 2.0
WG causes suicidal thoughts 14 7 2.0
Concerned about long-term effects of WG and treatment 70 35 2.0
Changed duties at work 37 90 0.4
* Values are percents.
† Differences of .1 indicate higher frequency among the Cleveland patients; differences of ,1 indicate higher frequency among the Groningen
patients.
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reading about further studies from international colleagues
that explore how different cultures and medical care systems
affect quality of life in patients with WG and other forms of
vasculitis.




Case Western Reserve University
Cleveland, OH
Reporting of bone mineral density values as T-scores
or Z-scores: comment on the article by Sowers et al
To the Editor:
We are writing in reference to the article by Sowers et
al in a recent issue of Arthritis & Rheumatism (Sowers M,
Lachance L, Jamadar D, Hochberg MC, Hollis B, Crutchfield
M, et al. The associations of bone mineral density and bone
turnover markers with osteoarthritis of the hand and knee in
pre- and perimenopausal women. Arthritis Rheum 1999;42:
483–9). Sowers and colleagues represent the bone mineral
density (BMD) values as Z-scores throughout the report.
However, the definition used in the report (in 3 different
places) for Z-score is typically understood to be that of a
T-score. A Z-score is defined as the difference between the
subject’s BMD and the age- and sex-matched population
average BMD normalized by that population’s standard devi-
ation. Sowers et al define the Z-score as the difference
between the subject’s BMD and “the mean value in a young
adult population,” which is a T-score. Thus, this is either a
consistent mislabeling of T-scores throughout the article, a
mistaken definition of a Z-score, or misuse of standard termi-
nology. In any case, the reader is left confused and not knowing
what the authors are really trying to communicate in this
otherwise interesting report.
John A. Shepherd, PhD
Sven Prevrhal, PhD




Drs. Shepherd and Prevrhal question the use of the
“Z-scores” label to describe BMD in our report. They raise 2
issues: Why use a score (what is the report trying to commu-
nicate), and should the score be labeled a Z-score or a
T-score?
With regard to the first issue, Z-scores have been
frequently used as a mechanism to standardize data from
diverse sources to a common reference. In our report, we
wanted the reader to be able to readily compare BMD across
the 3 anatomic locations (femoral neck, spine, and total body)
where the mean absolute values of BMD (gm/cm2) are not
comparable. However, we also wanted to use the Z-score for
communicating and comparing BMD differences over a 3-year
time interval across the 3 anatomic sites and between subjects
with and those without hand and knee osteoarthritis.
We used the Z-score label, not the T-score label, for the
following reasons. First, in the age range of this population
(24–45 years at baseline) and with a population of this size (n 5
601), the Z-score and the T-score are almost synonymous with
one another. Second, the T-score syntax has not been widely
applied to bone differences across time (one of the things we
wanted to communicate), whereas the Z-score syntax has been
widely used for communicating differences across time. Thus, we
assumed readers would understand this label more readily. Third,
Z-scores were the unit label in the manufacturer’s database of the
bone densitometer used in the study, although this manufactur-
er’s nomenclature has since been modified to that identified by
Shepherd and Prevrhal. Given that there was a rationale for using
the Z-score nomenclature, we thank Drs. Shepherd and Prevrhal
for acknowledging that we defined the reference for the Z-score
and that we consistently applied and adhered to this definition
throughout the article.
We hope our approach will encourage investigators to





Rarity of reported cases of vasculitis in Africa:
comment on the article by Bae et al
To the Editor:
We read with interest the article by Bae et al, in which
they reviewed the epidemiology of systemic lupus erythemato-
sus (SLE) in populations of African descent (1). Their excel-
lent review raises a related issue, that of the epidemiology of
vasculitis in Africa. The epidemiology of vasculitis in the
developed world has been poorly documented until relatively
recently (2). It is clear that in the developed world there are
some geographic and ethnic differences, but these are proving
difficult to elucidate.
Vasculitis in sub-Saharan Africa has been infrequently
described, and although there are no published epidemiologic
studies, descriptions of the pattern of rheumatic disease seen
in hospital clinics and in the community indicate that these
conditions are rarely seen, if at all (3). Indeed, one of us
(AOA) has never seen vasculitis associated with connective
tissue diseases in this area of the world, while working in both
the hospital and the community.
The reasons for these observations are obscure, but as
with SLE, there are various possible explanations, including
misdiagnosis and underreporting. Nevertheless, the high prev-
alence of infections such as hepatitis B ought to make some
forms of connective tissue disease–associated vasculitis at least
as common as in the West. Interestingly, antineutrophil cyto-
plasmic antibody positivity (tested by enzyme-linked immu-
nosorbent assay) has been reported in patients from West
Africa with malaria and tuberculosis who did not show any
overt clinical features of vasculitis (4). One intriguing hypothe-
LETTERS 2497
sis is that the putative etiologic factors relating to the preva-
lence of SLE in populations of African descent (the prevalence
gradient hypothesis) may also apply to the prevalence of
vasculitis in these populations.
A. O. Adebajo, MD
University of Sheffield
Sheffield, UK
R. A. Watts, DM
Ipswich Hospital
Ipswich, UK
1. Bae SC, Fraser P, Liang MH. The epidemiology of systemic lupus
erythematosus in populations of African ancestry: a critical review
of the “prevalence gradient hypothesis.” Arthritis Rheum 1998;41:
2091–9.
2. Watts RA, Scott DGI. Classification and epidemiology of the
vasculitides. Baillieres Clin Rheumatol 1997;11:191–217.
3. Adebajo AO, Birrel FA, Hazleman BL. The pattern of rheumatic
disorder seen among patients attending urban and rural clinics in
west Africa. Clin Rheumatol 1992;11:512–5.
4. Adebajo AO, Isenberg DA. Immunological aspects: tropical rheu-
matology. Baillieres Clin Rheumatol 1995;9:215–30.
Clinical Images: Radiographic progression of rheumatoid arthritis over twenty years
The patient was diagnosed as having rheumatoid arthritis (RA) in 1977, at the age of 56 years, based on symmetric arthritis of the
hands, wrists, and elbows, morning stiffness lasting 2 hours, and positive rheumatoid factor at a titer of 1:320. He did not have
nodules, and a plain posteroanterior radiograph of the hands at the time of diagnosis (A) showed nonspecific diffuse joint space
narrowing. Prior to the onset of RA, he had been taking clorazepate, imipramine, and diazepam, and he was reluctant to receive
any other drugs. In 1979 (B), there were typical changes of early RA, consisting of soft tissue swelling symmetrically around the
involved joints, joint space loss, juxtaarticular osteopenia, and marginal erosions, best seen here in the second and third
metacarpophalangeal (MCP) and third proximal interphalangeal (PIP) joints bilaterally. In 1982 (C), he had multiple and extensive
erosions in the MCP, PIP, and carpal joints and ulnar styloid. During 1985 (D) and 1986 (E), the erosive process progressed rapidly,
with extensive destruction of the bony architecture, subluxations in the MCP, PIP, and carpal joints, and ankylosis of the second,
third, fourth, and fifth PIP joints bilaterally. Ulnar deviation of the MCP joints was present mainly in the right hand. In 1994 (F),
severe generalized osteopenia and resorption and fragmentation of the MCP, PIP, and carpal joints was evident, and this continued
to progress through 1997 (G). Ulnar deviation of the MCP joints and radial deviation of the wrists produced the characteristic zigzag
appearance (E–G). The patient was last seen by us in March 1999, when he had 30 articular deformities of 40 recorded joints,
without synovitis, and was in Steinbrocker functional class III. He was treated during his .20-year disease course with aspirin 600
mg 4 times daily, naproxen 500 mg twice daily, and prednisone 5–10 mg/day, except for 5 months in 1982 when intramuscular gold
was started but had to be stopped due to a rash. Of interest, he has HLA–DRB1 *1302 and *1602, neither of which has been
commonly associated with skin reactions to intramuscular gold, nor do they contain the shared epitope sequences for RA.
Inmaculada del Rincón, MD
José F. Roldán, MD
University of Texas Health Science Center at San Antonio
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